Related Experiment Video
Updated: Jan 17, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory
Rafael Bolanos1, Rafael Araos2, Cecilia Gonzalez2
1Pfizer Value & Evidence Andean Cluster, Lima, Peru.
Insights
Maternal RSVpreF vaccination combined with nirsevimab for infants offers significant cost savings and improved health outcomes in Chile. This strategy is more cost-effective than nirsevimab alone for preventing RSV-LRTI.
Area of Science:
- Public Health
- Health Economics
- Infectious Disease Prevention
Background:
- Respiratory syncytial virus (RSV) is a major cause of infant lower respiratory tract illness (LRTI) in Chile.
- Infants, especially those born prematurely, face the highest risk of severe RSV-LRTI.
- Effective prevention strategies are crucial for reducing the burden of RSV in vulnerable infant populations.
Purpose of the Study:
- To evaluate the cost-effectiveness of different strategies for preventing RSV-LRTI in infants in Chile.
- To determine the economically justifiable price for maternal RSVpreF vaccination.
- To compare the cost-effectiveness of maternal vaccination plus nirsevimab versus nirsevimab alone.
Main Methods:
- A cohort model was developed to simulate RSV-LRTI prevention strategies.
- Calculated the economically justifiable price (EJP) for maternal RSVpreF vaccination (MV).
- Compared the cost-effectiveness of MV with nirsevimab (MV+N) against nirsevimab alone (NA), using published nirsevimab price ($260.00).
Main Results:
- Nirsevimab alone (NA) resulted in 20,247 cases and $57.2 million in total costs.
- Maternal vaccination plus nirsevimab (MV+N) yielded 23,906 cases but significantly lower costs of $28.7 million.
- MV+N demonstrated substantial cost savings of $28.4 million and improved quality-adjusted life-years compared to NA.
Conclusions:
- Maternal RSVpreF vaccination combined with nirsevimab for unprotected infants is the most resource-efficient strategy in Chile.
- This combined approach offers substantial cost savings compared to using nirsevimab alone.
- Implementing this strategy is recommended for optimal prevention of RSV-LRTI in infants.
Background:
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.
Research Design And Methods:
A cohort model was developed to evaluate cost-effectiveness of strategies preventing RSV-LRTI in infants. Using the model, we calculated the economically justifiable price (EJP) of maternal RSVpreF vaccination (MV) versus no intervention and then evaluated the cost-effectiveness of MV (cost/dose assumed at EJP) with complementary use of monoclonal antibody nirsevimab for unprotected infants (MV+N) versus nirsevimab alone (NA) to prevent RSV-LRTI. Nirsevimab published price was $260.00; costs/prices reported in 2023 US$.
Results:
NA yielded 20,247 cases (hospital: 3,773, emergency ward: 16,474) and $57.2 million (M) in total costs (medical: $6.3 M, intervention: $48.7 M, indirect: $2.2 M). MV+N yielded 23,906 cases (hospital: 3,137, emergency ward: 20,769) and $28.7 M in costs (medical: $4.8 M, intervention: $21.7 M [RSVpreF assumed $75.77/dose; nirsevimab procured $260.00/dose], indirect: $2.2 M). With costs lower by $28.4 M and increased quality-adjusted life-years, MV+N would be cost-saving versus NA.
Conclusions:
RSVpreF vaccination among pregnant women along with nirsevimab for unprotected infants in Chile would be the most efficient use of resources, yielding substantial cost savings compared to use of nirsevimab alone.
More Related Videos
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:30Preventive Healthcare Services